… The aim of this study was to assess the efficacy and safety in an “everyday clinical practice”
population of anticoagulant-naïve patients with atrial fibrillation (AF) treated with dabigatran …

… In this systematic review, real-world evidence shows that dabigatran is comparable with
warfarin in preventing ischemic stroke in patients with NVAF. However, dabigatran is associated …

… practice. Therefore, we compared the effectiveness and safety of dabigatran with warfarin in
clinical practice … events among AF patients using dabigatran compared with warfarin, and (2) …

… In the RE-LY clinical trial, dabigatran presented a better effectiveness/ safety profile when …
of the real-world setting. We aimed to assess the performance of dabigatran in real-world …

… safety of dabigatran, there may be differences in the drug use and outcomes in routine clinical
practice … In this retrospective chart review study, we describe the use of dabigatran in 160 …

… to assess the effectiveness and safety of dabigatran (direct thrombin inhibitor) vs.
acenocoumarol (vitamin K antagonist) in patients with atrial fibrillation (AF) in daily clinical practice. …

… all safety domains regardless of the TTR, whereas for outcomes of mortality, vascular and
non-haemorrhagic events the higher dose of dabigatran … both doses of dabigatran (110mg and …

… safety of dabigatran in ‘real-world’ clinical practice As shown in ▶Table 1 and ▶Figure 1, the
data for dabigatran in ‘real world’ clinical practice … RE-LY findings with dabigatran. In the RE…

… for the comparison between dabigatran and warfarin (Figure 3). The risk of stroke was lower
with dabigatran than warfarin, and this superiority of dabigatran was more pronounced in …

… In “real-world” practice, anticoagulant … safety of dabigatran treatment in “real-world” Japanese
NVAF patients. The aim of this study is to assess the effectiveness and safety of dabigatran …